Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2021

01-01-2021 | Liver Transplantation | Original Article

A Stepwise Evaluation of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure to Optimize the Indication for Urgent Liver Transplantation

Authors: Xueyun Zhang, Yue Ying, Pu Zhou, Xiaoqin Liu, Ruidong Li, Yifeng Tao, Minhui Dong, Beidi Zhu, Xun Qi, Qianqian Wang, Xiaofei Zhang, Jingwen Wu, Jianming Zheng, Weifeng Zhao, Wenhong Zhang, Zhengxin Wang, Jiming Zhang, Yuxian Huang

Published in: Digestive Diseases and Sciences | Issue 1/2021

Login to get access

Abstract

Background

Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a dynamic but reversible disease.

Aim

We aimed to clarify whether the change in Chinese Group on the Study of Severe Hepatitis B-ACLF (COSSH-ACLF) grade in HBV-ACLF patients can be used to predict prognosis, and to explore the appropriate conditions for performing urgent liver transplantation.

Methods

We assessed the COSSH-ACLF grades of HBV-ACLF patients at different time points from June 2013 to May 2019 at Huashan Hospital in Shanghai, China, and analyzed the relationship between the change in grade and patient prognosis.

Results

A total of 207 HBV-ACLF patients were enrolled, of which 79 underwent urgent liver transplantation. Their COSSH-ACLF grades were calculated at diagnosis, 3–7 days after diagnosis, and on the final day. Most of the final ACLF grades were consistent with their corresponding grades at days 3–7 after diagnosis (62.5%), while only 44.5% were in accordance with the initial grades at diagnosis. In patients who had a poor prognosis (initial ACLF-3 and ACLF-2 or -3 at days 3–7), the 28-day survival rate was 93.3% in those who underwent transplantation and 6.8% in those who did not (P < 0.0001). However, in patients who had a good prognosis (ACLF-0 or ACLF-1 at days 3–7), the 28-day survival rate was 100% in transplanted patients and 91.5% in non-transplanted patients (P = 0.236).

Conclusions

Reevaluation of the COSSH-ACLF grade 3–7 days after diagnosis could potentially show an indication for urgent liver transplantation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bernal W, Jalan R, Quaglia A, et al. Acute-on-chronic liver failure. Lancet. 2015;386:1576–1587.CrossRef Bernal W, Jalan R, Quaglia A, et al. Acute-on-chronic liver failure. Lancet. 2015;386:1576–1587.CrossRef
2.
go back to reference Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int. 2014;8:453–471.CrossRef Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int. 2014;8:453–471.CrossRef
3.
go back to reference Moreau R, Jalan R, Gines P, et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437.CrossRef Moreau R, Jalan R, Gines P, et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437.CrossRef
4.
go back to reference Gustot T, Fernandez J, Garcia E, et al. Clinical course of acute-on chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–252.CrossRef Gustot T, Fernandez J, Garcia E, et al. Clinical course of acute-on chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–252.CrossRef
5.
go back to reference West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther. 2017;45:983–990.CrossRef West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther. 2017;45:983–990.CrossRef
6.
go back to reference Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: an observational study. PLoS ONE. 2017;12:e0186715.CrossRef Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: an observational study. PLoS ONE. 2017;12:e0186715.CrossRef
7.
go back to reference Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut.. 2018;67:2181–2191.CrossRef Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut.. 2018;67:2181–2191.CrossRef
8.
go back to reference Hernaez R, Solà E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.CrossRef Hernaez R, Solà E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.CrossRef
9.
go back to reference European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433–485.CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433–485.CrossRef
10.
go back to reference Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology.. 2007;45:797–805.CrossRef Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology.. 2007;45:797–805.CrossRef
11.
go back to reference Massie AB, Chow EK, Wickliffe CE, et al. Early changes in liver distribution following implementation of Share 35. Am J Transplant. 2015;15:659–667.CrossRef Massie AB, Chow EK, Wickliffe CE, et al. Early changes in liver distribution following implementation of Share 35. Am J Transplant. 2015;15:659–667.CrossRef
12.
go back to reference Brooks JT, Koizumi N, Neglia E, et al. Improved retransplant outcomes: early evidence of the share35 impact. HPB (Oxford). 2018;20:649–657.CrossRef Brooks JT, Koizumi N, Neglia E, et al. Improved retransplant outcomes: early evidence of the share35 impact. HPB (Oxford). 2018;20:649–657.CrossRef
13.
go back to reference Goel A, Kim WR, Pyke J, et al. Liver simulated allocation modeling: were the predictions accurate for share 35? Transplantation. 2018;102:769–774.CrossRef Goel A, Kim WR, Pyke J, et al. Liver simulated allocation modeling: were the predictions accurate for share 35? Transplantation. 2018;102:769–774.CrossRef
14.
go back to reference Murken DR, Peng AW, Aufhauser DD Jr, Abt PL, Goldberg DS, Levine MH. Same policy, different impact: center-level effects of share 35 liver allocation. Liver Transpl. 2017;23:741–750.CrossRef Murken DR, Peng AW, Aufhauser DD Jr, Abt PL, Goldberg DS, Levine MH. Same policy, different impact: center-level effects of share 35 liver allocation. Liver Transpl. 2017;23:741–750.CrossRef
15.
go back to reference Cholongitas E, Germani G, Burroughs AK. Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol. 2010;7:659–668.CrossRef Cholongitas E, Germani G, Burroughs AK. Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol. 2010;7:659–668.CrossRef
16.
go back to reference Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011;54:1297–1306.CrossRef Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011;54:1297–1306.CrossRef
17.
go back to reference Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–266.CrossRef Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–266.CrossRef
18.
go back to reference Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–832.CrossRef Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–832.CrossRef
19.
go back to reference Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol. 2000;32:157–170.CrossRef Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol. 2000;32:157–170.CrossRef
20.
go back to reference Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–1660.CrossRef Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–1660.CrossRef
21.
go back to reference Abad-Lacruz A, Cabré E, González-Huix F, et al. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child–Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol. 1993;88:382–387.PubMed Abad-Lacruz A, Cabré E, González-Huix F, et al. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child–Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol. 1993;88:382–387.PubMed
22.
go back to reference Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61:1038–1047.CrossRef Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61:1038–1047.CrossRef
23.
go back to reference Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10.CrossRef Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10.CrossRef
24.
go back to reference Asrani SK, Simonetto DA, Kamath PS. Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2015;13:2128–2139.CrossRef Asrani SK, Simonetto DA, Kamath PS. Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2015;13:2128–2139.CrossRef
25.
go back to reference Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11:461–471.CrossRef Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11:461–471.CrossRef
26.
go back to reference Shalimar S, Kumar D, Vairaja PK, et al. Acute on chronic liver failure because of acute hepatic insults: etiologies, course, extrahepatic organ failure and predictors of mortality. J Gastroenterol Hepatol. 2016;31:856–864.CrossRef Shalimar S, Kumar D, Vairaja PK, et al. Acute on chronic liver failure because of acute hepatic insults: etiologies, course, extrahepatic organ failure and predictors of mortality. J Gastroenterol Hepatol. 2016;31:856–864.CrossRef
27.
go back to reference Bajaj JS, Oleary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extra-hepatic organ failures. Hepatology. 2014;60:250–256.CrossRef Bajaj JS, Oleary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extra-hepatic organ failures. Hepatology. 2014;60:250–256.CrossRef
28.
go back to reference Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67:1870–1880.CrossRef Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67:1870–1880.CrossRef
29.
go back to reference Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46:1853–1862.CrossRef Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46:1853–1862.CrossRef
30.
go back to reference Kribben A, Gerken G, Haag S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:782–789.CrossRef Kribben A, Gerken G, Haag S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:782–789.CrossRef
31.
go back to reference Banares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57:1153–1162.CrossRef Banares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57:1153–1162.CrossRef
32.
go back to reference Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006;10:R108.CrossRef Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006;10:R108.CrossRef
33.
go back to reference Bañares R, Ibáñez-Samaniego L, Torner JM, et al. Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therap Adv Gastroenterol. 2019;12:1756284819879565.CrossRef Bañares R, Ibáñez-Samaniego L, Torner JM, et al. Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therap Adv Gastroenterol. 2019;12:1756284819879565.CrossRef
Metadata
Title
A Stepwise Evaluation of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure to Optimize the Indication for Urgent Liver Transplantation
Authors
Xueyun Zhang
Yue Ying
Pu Zhou
Xiaoqin Liu
Ruidong Li
Yifeng Tao
Minhui Dong
Beidi Zhu
Xun Qi
Qianqian Wang
Xiaofei Zhang
Jingwen Wu
Jianming Zheng
Weifeng Zhao
Wenhong Zhang
Zhengxin Wang
Jiming Zhang
Yuxian Huang
Publication date
01-01-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06149-x

Other articles of this Issue 1/2021

Digestive Diseases and Sciences 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.